Yipinhong subsidiary gains NMPA approval for polyethylene glycol constipation drug
Yipinhong Pharmaceutical’s wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, received a Drug Registration Certificate from China’s National Medical Products Administration (NMPA) for its Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. Approved as a Class 3 chemical drug, it is indicated for chronic constipation and fecal impaction. The approval allows domestic marketing, enriching the company’s chronic disease product pipeline.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that the NMPA's consistency evaluation is a real improvement that raises drug quality standards in China.
- Both acknowledge that this single approval won't dramatically change Yipinhong's overall revenue in the short term.
- Both agree that Yipinhong's existing distribution network and experience with gastrointestinal products are legitimate advantages.
- Both recognize that the competitive timeline—how many other companies already have similar approvals—is a key factual gap neither fully checked.
Points of contention
- Eastern Agent sees the approval as a meaningful step in China's long-term push for pharmaceutical self-sufficiency, while Neutral Agent views it as a routine generic approval with little commercial impact.
- Eastern Agent argues that consistency evaluation gives Yipinhong a real edge in hospital procurement, while Neutral Agent says it's just a baseline requirement that many competitors will also meet.
- Neutral Agent insists on immediate market share and pricing data to judge the approval's value, while Eastern Agent says that demand for instant numbers misses how value builds over time in China's system.
- Eastern Agent frames the approval as part of a strategic national goal, while Neutral Agent calls that a 'category error' that confuses macro trends with a single stock's prospects.
Blind spots
- Neither side checked how many other companies already have consistency-evaluated approvals for this polyethylene glycol product, which is crucial for judging first-mover advantage.
- Both ignored actual pricing data from China's Volume-Based Procurement system, which has been driving generic drug prices down by 50-90% and directly affects profit margins.
- The debate overlooked how Yipinhong's other gastrointestinal products might create cross-selling opportunities with this new approval in hospital settings.
- Neither side considered the specific timeline of when provincial tender results will come out, which is where the real commercial impact will be seen.
WorldAttention’s read
This debate shows two valid but incomplete perspectives on Yipinhong's NMPA approval for polyethylene glycol oral solution. Eastern Agent correctly highlights that consistency evaluation is a real gatekeeping mechanism in China's hospital procurement system, and that the approval fits into a broader national push for pharmaceutical self-sufficiency. Neutral Agent rightly points out that this is a routine generic approval in a crowded, low-margin market, and that regulatory milestones don't guarantee commercial success. The key blind spots are factual: neither side checked how many competitors already have similar approvals, and both ignored actual pricing data from China's Volume-Based Procurement system. The truth lies in the middle—this is a modest positive for Yipinhong, giving it a necessary ticket to compete in hospital tenders, but it's not a game-changer. The real story will be written in the next provincial tender results, where pricing and market share will determine whether this approval actually moves the needle.
Reporting timeline
Yipinhong Subsidiary Gets China Drug Approval for Polyethylene Glycol Oral Solution
Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has received a Drug Registration Certificate from China's National Medical Products Administration for a compound polyethylene glycol (3350) electrolyte oral solution. The drug, classified as a Category 3 chemical drug, is deemed to have passed consistency evaluation with the original brand. Its approved indications are the treatment of chronic constipation and fecal impaction. According to data from Menet, the sales scale of polyethylene glycol in Chinese urban and county public hospitals was approximately 221 million yuan in 2025. This approval qualifies the company to market the drug domestically, which the company states will further enrich its product pipeline and enhance its competitiveness in the chronic disease drug market.
Read sourceYipinhong Subsidiary Receives Drug Registration Certificate for Compound Polyethylene Glycol Oral Solution
On September 20, Yipinhong Pharmaceutical Co., Ltd. announced that its subsidiary has received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution, approved by China's National Medical Products Administration. The approval qualifies the company to sell this drug specification in the domestic market, enriching its product pipeline and enhancing competitiveness in the chronic disease medication sector. The drug is indicated for treating constipation and fecal impaction. According to data from Menet, polyethylene glycol sales in China's urban and county hospitals are projected to reach a certain level by 2025. The report also notes that by mid-2026, Yipinhong achieved revenue of RMB 492 million and net profit attributable to shareholders of the parent company of RMB 485 million. The source is Caizhong She via East Money.
Yipinhong Subsidiary Receives Drug Registration Certificate for Polyethylene Glycol Oral Solution
Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently received a Drug Registration Certificate from the National Medical Products Administration (NMPA) for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. The approved specification is 25ml per bag, with the drug approval number Guoyao Zhunzi H20265982. The product is classified as a Chemical Drug Class 3 and is deemed to have passed consistency evaluation with the reference listed drug. This regulatory approval allows the subsidiary to manufacture and market the product in China.
Read sourceShow 3 older updatesHide older updates
Yipinhong Subsidiary Gets Drug Registration for Polyethylene Glycol Oral Solution
Yipinhong (300723) announced on September 20 that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution from China's National Medical Products Administration. According to the approved package insert, the drug is indicated for the treatment of chronic constipation and fecal impaction. The company applied for registration as a Class 3 chemical drug, which is deemed to have passed consistency evaluation. The announcement was reported by People's Finance News and sourced from stockstar_securities_news.
Read source3G Pharma Subsidiary Gets Registration Certificate for Polyethylene Glycol Oral Solution
3G Pharma (300723.SZ) announced on September 20 that its wholly-owned subsidiary, Guangzhou 3G Pharma Co., Ltd., has received a Drug Registration Certificate from China's National Medical Products Administration for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. According to the approved package insert, the oral solution is indicated for the treatment of chronic constipation and fecal impaction. The active ingredient, polyethylene glycol 3350, produces a laxative effect through osmotic action in the intestine, with the onset of action varying depending on the severity of the condition. The electrolyte components in the formulation help maintain sodium, potassium, and water balance in the body.
Read sourceYipinhong Receives NMPA Approval for Compound Polyethylene Glycol Electrolyte Oral Solution
Yipinhong Pharmaceutical Co., Ltd. announced on September 20 that it has received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for its Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. According to the approved package insert, the drug is indicated for the treatment of chronic constipation and fecal impaction. The company registered the product as a Class 3 chemical drug, which is deemed to have passed consistency evaluation. The news was reported by Securities Times Network and published on East Money's company reports section.
Read source